Permeation Enhancer-based Ionogel Shows Remarkable Potential for Oral Insulin Delivery.

The increased focus on peptide therapeutics has created an unmet need for technologies and materials enabling therapeutic efficacy after oral administration. Currently, permeation enhancers are the gold standard for oral peptide delivery, with sodium decanoate being one of the most widely tested in preclinical and clinical studies. This study aims to develop and investigate a decanoate-based ionic liquid (IL) inspired by the reported absorption enhancing effect of choline geranate (CAGE) IL. The delivery system is prepared by loading choline decanoate with insulin and upon optimization of the ratio, the chC 1:2 lead formulation shows gel-like rheological properties. Its high viscosity and hydrophobicity results in slow dissolution in vitro and sustained absorption in vivo. In vivo data show that it can mediate a 7- and a 13-fold higher oral bioavailability of insulin (6.5%) compared to CAGE (0.9%) and sodium decanoate (0.5%), respectively. Histological evaluation reveals that exposure to chC 1:2 does not affect villi morphology, while 15 min exposure to CAGE significantly reduces villi height. The villi erosion observed is transient and not significantly different from that observed with sodium decanoate. These results showcase the high potential of the chC 1:2 as an oral drug delivery vehicle.